Hussman Strategic Advisors Inc. Takes Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Hussman Strategic Advisors Inc. purchased a new stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 42,000 shares of the company's stock, valued at approximately $499,000. Hussman Strategic Advisors Inc. owned about 0.06% of Nurix Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of the business. FMR LLC lifted its stake in shares of Nurix Therapeutics by 1,711.9% in the fourth quarter. FMR LLC now owns 10,634,231 shares of the company's stock valued at $200,349,000 after buying an additional 10,047,329 shares in the last quarter. RA Capital Management L.P. bought a new position in shares of Nurix Therapeutics in the fourth quarter valued at $25,120,000. Soleus Capital Management L.P. lifted its stake in shares of Nurix Therapeutics by 97.3% in the fourth quarter. Soleus Capital Management L.P. now owns 2,102,833 shares of the company's stock valued at $39,617,000 after buying an additional 1,036,999 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Nurix Therapeutics during the fourth quarter valued at about $16,447,000. Finally, Boxer Capital Management LLC bought a new position in shares of Nurix Therapeutics during the fourth quarter valued at about $10,608,000.

Nurix Therapeutics Price Performance

Shares of NRIX stock remained flat at $11.25 on Tuesday. 640,926 shares of the company were exchanged, compared to its average volume of 846,664. The stock's 50-day simple moving average is $11.47 and its two-hundred day simple moving average is $13.52. Nurix Therapeutics, Inc. has a 1 year low of $8.18 and a 1 year high of $29.56. The stock has a market capitalization of $860.05 million, a P/E ratio of -4.31 and a beta of 2.15.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.79) by $0.27. Nurix Therapeutics had a negative return on equity of 45.26% and a negative net margin of 234.57%. The company had revenue of $44,056 billion during the quarter, compared to the consensus estimate of $16.26 million. On average, research analysts expect that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NRIX has been the subject of several recent research reports. Stephens reiterated an "overweight" rating and issued a $30.00 target price on shares of Nurix Therapeutics in a research note on Thursday, July 10th. Wall Street Zen upgraded shares of Nurix Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, June 21st. Stifel Nicolaus reduced their target price on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday, April 9th. Oppenheimer reduced their price objective on shares of Nurix Therapeutics from $32.00 to $30.00 and set an "outperform" rating for the company in a research note on Thursday, July 10th. Finally, UBS Group reduced their price objective on shares of Nurix Therapeutics from $30.00 to $26.00 and set a "buy" rating for the company in a research note on Thursday, July 10th. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. According to MarketBeat.com, Nurix Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $29.31.

Insider Activity

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,377 shares of the business's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total value of $38,835.50. Following the completion of the transaction, the insider directly owned 61,516 shares of the company's stock, valued at approximately $707,434. The trade was a 5.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Houte Hans Van sold 6,198 shares of the business's stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $11.33, for a total value of $70,223.34. Following the completion of the transaction, the chief financial officer directly owned 33,724 shares of the company's stock, valued at $382,092.92. The trade was a 15.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 12,013 shares of company stock worth $137,096 in the last quarter. 7.40% of the stock is owned by insiders.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.